Private equity finds the right medicine in healthcare

The healthcare private equity (PE) landscape is experiencing a remarkable surge, defying the headwinds of high borrowing costs. According to Bain & Company's recently released 'Global Healthcare Private Equity Report 2025,' the sector achieved $115 billion in deal value during 2024—the second-highest figure on record, trailing only behind the exceptional $151 billion seen in 2021. North American deals dominated the landscape, accounting for 65 per cent of total value, while Europe and Asia Pacific contributed 22 per cent and 12 per cent respectively. Biopharma remains the focus of large deals The biopharma sector continues to attract the largest deals, though with interesting nuances. While overall deal volume has declined since 2020, major transactions like the Catalent deal ($16.5 billion) and the Sanofi deal ($17.3 billion) demonstrate that investors haven't lost their appetite for transformative opportunities. However, the sector isn't without its challenges. A persistent valuation gap between buyers and sellers means that companies coming to market must present compelling value-creation plans to justify their asking prices. The sector is also grappling with reduced spending on drug innovation and the impact of patent expirations on pharmaceutical companies' budgets, creating a more cost-conscious environment. Investment leads in IT and clinical trial infrastructure Perhaps the most intrigui

This article was originally published on February 01, 2025.